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ANNEXE: 
TRANSPLANTATION 
TOLERANCE FROM A 
HISTORICAL PERSPECTIVE1 
Thomas E. STARZL, Rolf M. ZINKERNAGEL 
Although transplantation immunology as a distinctive field began with the devel-
opment of experimental models that showed the feasibility of bone marrow 
transplantation, organ engraftment was accomplished first in humans, and was 
thought for many years to occur by drastically different mechanisms. Here, we 
present our view of the concepts of allograft acceptance and acquired tolerance 
from a historical perspective, and attempt to amalgamate them into simple and 
unifying rules that might guide improvements in clinical therapy. 
Our paradigm of transplantation immunology (reviewed in [1]) had its origin in 
the nineteenth century. After the cellular, humoral and complement constituents 
of the immune response were discovered (see timeline), evidence emerged that 
an immune reaction was responsible for the failure of transplanted tissue and 
most tumour allografts to survive indefinitely [2J. When transplantation research 
declined during and after the First World War, these early accomplishments 
faded. Similarly, the significance of the neonatal tolerance shown in tumour and 
viral-infection models was not fully appreciated until Burnet's formulation of 
the tolerance and clonal-selection hypothesis [3J. Finally, the phenomenon of 
immune ignorance was first shown in 1934 [4], but discounted until its redis-
covery many years later [5, 6]. 
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Modern transplantation immunology is often dated to the experiments by 
Medawar in 1944, which showed that skin allograft rejection is a host-versus-
graft (HVG) response [7], the cell-mediated features of which were later 
defined by Mitchison [8]. The term major histocompatibility complex (MHC) 
was introduced by Gorer, Lyman and Snell [9] for the genetic locus that 
encodes antigens associated with allograft rejection, tumour surveillance and 
other expressions of cell-mediated immunity. The MHC-restricted mecha-
nisms of T-cell recognition of, and response to, antigens, viruses and. other 
intracellular microorganisms were elucidated in the 1970s (reviewed in [1 OJ). 
i!l 1 Reprinted by pennission from Nature Reviews Immunology Vol. I, No.3, pp. 233-239. Copy-
~ @ right © Macmillan Magazines Ltd. 
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Non-cytopathic microorganisms (for example, lymphocytic choriomeningitis 
virus (LCMV) in mice) are controlled primarily by cytotoxic T lymphocytes 
(CTLs) that recognize as "non-self' host cells which display complexes 
composed of self-MHC molecules and peptides derived from the infecting 
microorganism. Allograft rejection was the apparent transplantation equiva-
lent of the host-versus-pathogen adaptive immune response, but the specific 
mechanisms governing allograft acceptance remained a puzzle. 
The avoidance of rejection 
Bone marrow transplantation, 1953-1989. In experiments inspired by Owen's 
description of blood-cell chimerism in freemartin cattle [11], and by the recog-
nition by Burnet and Fenner [3] of the observation's significance, Billingham, 
Brent and Medawar [12] showed between 1953 and 1956 that allogeneic spleen 
and bone marrow (BM) cells induce tolerance when they are not rejected by the 
incompletely developed immune system of neonatal mouse recipients, and that 
the tolerance extends to donor strain skin allografts. This model is analogous to 
successful BM-cell transplantation in humans whose immune-deficiency 
diseases make host cytoablation unnecessary [13]. During 1955-1956, similar 
tolerance was induced in adult mice whose mature immune system was cytoab-
lated with supralethal total body irradiation (TBl) [14]. The mouse model 
evolved into clinical BM transplantation for a wide range of indications [15]. 
The avoidance of lethal graft-versus-host disease (GvHD) in the experimental 
tolerance models and in humans requires a close tissue match. Until human-
leukocyte-antigen (HLA) matching became available in 1968, a decade after the 
discovery by Dausset and van Rood of the first HLA antigens, prolonged survival 
after clinical BM transplantation was limited to a single case [16]. GvHD seemed 
to be a mirror-image version of tissue and organ rejection (HVG) in that the host 
(fig. Ib), rather than the graft (fig. la), was the immune target. 
The unidirectional mixed-lymphocyte-reaction assays, introduced in 1964, 
became widely accepted "minitransplant models", reinforcing the idea that one-
way immune reactions - GvH or HVG - were induced after BM and organ trans-
plantation, respectively. Accordingly, successful BM transplantation was 
generally viewed as total replacement of the recipient immune apparatus, even 
after the discovery in 1989 that recipient leukocytes could be found in the blood of 
essentially all human "complete donor BM chimeras" [17]. The early hypothesis 
that donor and recipient immune-competent cells might coexist, become mutually 
non-reactive and even function collaboratively (for example, in a joint response to 
a new infection) [18, 19] lacked experimental support and was abandoned. 
Clinical organ transplantation, 1959-1991. The strategy of co-transplanting 
BM and skin allografts to supralethally irradiated mice was extended in the 
late 1950s by John Mannick and David Hume to kidneylBM transplantation in 
irradiated beagle and outbred dogs, but yielded only a single survival 
exceeding I month (73 days). Although the survival of dog kidney transplants 
was even worse when the adjunct BM was omitted, six humans conditioned 
with sublethal doses of TBI (4.5 Gy) achieved renal allograft function for at 
least I vear (the first in Boston and the next five in Paris) l20-22]. The era of 
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Fig. 1. Old and new views of transplantation immunology. 
a. Illustrates the early conceptualization of immune mechanisms in organ 
transplantation in terms of a unidirectional host-versus-graft (HVG) response. 
Although this readily explained organ rejection, it limited possible explana-
tions of organ engraftment. b. A mirror image of (a) and depicts the early 
understanding of successful bone marrow (8M) transplantation as a complete 
replacement of the recipient immune system by that of the donor, with the 
potential complication of an unopposed lethal unidirectional graft-versus-host 
(GvH) response: that is, rejection of the recipient by the graft. c. Shows the 
current view of bidirectional and reciprocally modulating immune responses 
of coexisting immune-competent cell populations that lead to organ engraft-
ment, despite a usually dominant HVG reaction. The transplanted organ, 
which initially loses most of its passenger leukocytes, apparently remains an 
important site for donor precursor and stem cells (bone silhouette) [47J. 
d. Represents the current conceived mirror image of (e) and shows the reversal 
of the size proportions of the reciprocally modulating donor and recipient 
populations of immune cells after successful BM transplantation. 
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drug immunosuppression then began after Schwartz and Dameshek [23] 
showed that the anti-leukaemic drug 6-mercaptopurine was immunosuppres-
sive in rabbits. When about 5% of dog kidney recipients treated by Caine and 
Zukoski with 6-mercaptopurine, or its analogue azathioprine, survived for 
2 100 days, human trials were undertaken by Murray and colleagues [24]. In 
the sixth case of kidney transplantation, a renal allograft from a non-related 
donor functioned for 17 months after its transplantation under azathioprine-
based therapy [24]. 
At first, the results with drug therapy were no better than with TBI. However, 
when large doses of prednisone were added to azathioprine in response to clini-
cally diagnosed rejections, two key observations were made, as described in the 
title of a report of ten cases: "The reversal of rejection in human renal homografts 
with subsequent development of homograft tolerance" [25]. The partial tolerance 
referred to the time-related diminution of dependence on immunosuppression, 
which eventually was stopped [26] in two of the patients whose grafts still func-
tion after 39 years. In 1966, heterologous anti-lymphoid globulin (ALO) was 
added in a triple-agent protocol [27] that was used for the first successful trans-
plantation of the human liver in July 1967 and heart in January 1968. 
The repeated demonstration that organ transplantation was feasible without 
adjunct BM cells, together with the striking differences between organ and BM 
transplantation (table 1), led to a consensus by the early 1960s that organ engraft-
ment did not involve donor leukocyte chimerism. This conclusion ostensibly was 
congruent with the identification of the "sessile" and/or recirculating passenger 
leukocytes of BM origin contained in all organs, as the immunogenic component 
of allografts [28-30]. When it was subsequently learned that most of these 
"passenger leukocytes" are replaced in the engrafted organ by comparable recip-
ient cells, it was assumed that the donor leukocytes had undergone immune 
destruction either within the graft or after their migration to host lymphoid organs, 
with selective preservation of the specialized parenchymal cells of the organ. 
Table I. Differences of organ and bone marrow transplantation 
Feature Organ Bone marrow 
Host cytoablation No Yes' 
HLA matching Not essential Critical 
Principal complication Rejection GvHD 
Immunosuppression free Uncommon Common 
Term for success Acceptance Tolerance 
* This therapeutic step allows a relatively unopposed graft-versus-host reaction and accounts 
for the other differences. GvHD, graft-versus-host disease; HLA, human leukocyte antigen. 
The resulting explanation of organ engraftment by means other than the 
chimerism-associated mechanisms of BM transplantation was not chalIeng~d 
until small numbers of multilineage donor haematopoietic cells (that IS, 
microchimerism) were shown in 1992 in the tissues or blood of 30 long-
surviving human liver or kidney allograft recipients [31, 32]. Organ engraft-
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ment (fig. Ie) and BM-cell engraftment (fig. Id) seemed to be mirror images 
with reversed proportions of donor-recipient haematolymphopoietic cells, 
placing both in a continuum of leukocyte chimerism-associated tolerance 
models that could be related to the neonatal mouse experiments of Bill-
ingham, Brent and Medawar [12], and to Owen's original observation of 
blood-cell chimerism in freemartin cattle [11]. 
Mechanisms of non-reactivity 
Chimerism and clonal deletion. clonal exhaustion was postulated between 1959 
and 1968 to explain acquired non-reactivity to a variety of antigens [23, 33, 34], 
including allogeneic cells [18] and, in 1969, as the basis of organ tolerance [35]. 
However, the existence and importance of this mechanism have only been 
formally established since 1990 (refs [36, 37]). With the finding in 1992 of 
microchimerism years after transplantation in surviving organ recipients, it was 
deduced that the crucial period for allo-engraftment was irrunediately post-trans-
plantation and consisted of " ... [acute] responses of coexisting donor and 
recipient [irrunune] cells, each to the other, causing reciprocal clonal exhaustion, 
followed by peripheral clonal deletion" (fig. 2) [31]. Although this hypothesis has 
been validated experimentally [1, 26, 38], the molecular pathways of deletion-
associated apoptosis observed in transplant models are not yet fully understood. 
Moreover, the role of the late microchirnerism has been controversial [39]. 
Immunosuppression 
Failure 
Immune H~--------=:;?::=~-=:;;;~=-~:=;;;:=-=~", .. ~ .. ;: .. ;;: .. ;: .. ;;: .. :7' •. ;;0. Success 
reaction •••••• 
Donor 
Time after organ transplantation 
Fig. 2. Contemporaneous HVG (upright curves) and GvH (inverted curves) 
responses following organ transplantation. 
If some degree of reciprocal clonal exhaustion is not induced and main-
tained (usually requiring protective immune suppression), one cell 
population will destroy the other. In contrast to the usually dominant host-
versus-graft (HVG) reaction of organ transplantation (shown here), the 
graft-versus-host (GvH) reaction usually is dominant in the cytoablated 
bone marrow recipient. Therapeutic failure with either type of transplanta-
tion implies the inability to control one, the other, or both of the responses. 
--- -_.- .. _' ,~.-- .. --- .---. 
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Immune ignorance. We believe that antigen that fails to reach organized 
lymphoid collections is ignored by the immune system [40]. In an early 
example, Stone, Owings and Gey [4] reported that parathyroid tissue, which 
had been cultured for 2 weeks and transplanted into loose areolar subcuta-
neous tissue, functioned for prolonged periods in dog and human recipients. 
Long regarded as not credible, their findings are explained, in retrospect, by 
two features of the procedure. The first was the choice of a subcutaneous 
implantation site, which, like other privileged sites (for example, hamster 
cheek pouch and brain), has limited lymphatic drainage. Illustrating this prin-
ciple in 1957, Frey and Wenk showed that no immune response is induced by 
otherwise sensitizing chemicals if the antigen is prevented from migrating to 
draining lymph nodes or spleen, an observation subsequently extended to skin 
allografts by Barker and Billingham [5]. 
The second feature of the Stone procedure became apparent with the 
demonstration by Lafferty and co-workers [6] that tissue culture comparable 
with that used 4 decades earlier in the parathyroid experiments depletes 
endocrine tissue of passenger leukocytes that are capable of migrating to 
host lymphoid organs. Similarly, allografts lose immunogenicity when their 
passenger leukocytes are removed from tissues or organs in "parking exper-
iments" [28-30] or by other means. The reduced immunogenicity has been 
explained by the elimination of leukocyte subsets expressing MHC class II 
antigens or co-stimulatory molecules, such as B7 (CD80/86) - for example, 
donor dendritic cells [41]. However, passenger leukocytes might be immu-
nogenic primarily because they can migrate to lymphoid organs, whereas 
the fixed parenchymal cells generally cannot. The results of experiments 
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with fractionated liver cell suspensions [42] and with tumour cells lacking 
MHC class II or so-called "second signals" (43] are consistent with this 
alternative hypothesis. 
Immune ignorance of heart allografts has been definitively studied during the 
past 5 years in mutant (alylaly) mice that have normal T lymphocytes and a 
spleen, but lack Peyer's patches and lymph nodes. Cardiac allografts drained 
into the circulation by vascular anastomosis are indolently rejected, but when 
splenectomy is also performed, the hearts are permanently accepted [44]. In 
addition to exemplifying immune ignorance, the results contradicted the 
historical dogmas that the immune response to primarily vascularized organs 
does not require the presence of host lymphoid organs, and that intragraft 
responses are generated "directly" in the transplanted organ. 
Collaborative mechanisms 
With the recognition in the 1990s that the key event in allograft acceptance is 
cell migration and relocation [31] and that the adaptive immune response to 
non-cytopathic organisms is determined by the migration patterns of the 
pathogen [40,45], the analogies between infection and transplantation shown in 
box 1 were obvious. In essence, the dose, kinetics and localization of antigen in 
or outside lymphatic tissl,les regulate immune responsiveness or unresponsive-
ness not only against infection and allografts, but also against tumours and self. 
An adaptive immune response could then be viewed as "a balance between 
potentially reactive lymphocytes versus the composition, quantity, kinetics, and 
distribution of antigen (foreign or extralymphatic self) within the host" [1]. 
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In this context, the presumably rare Stone-Lafferty graft (box I a) is ignored 
because it contains so few leukocytes capable of migrating to organized host 
lymphoid collections. By contrast, the transplant outcomes (including irre-
versible acute rejection; box I b) are analogous with those following spreading 
blood-borne infections by non-cytopathic microorganisms, in which variable 
combinations of clonal exhaustion-deletion and immune ignorance might 
result in degrees of responsiveness and non-responsiveness. At one extreme, 
clonal exhaustion induced by overwhelming numbers of leukocytes (box Ie) 
might allow unrestricted subsequent passage of donor cells between lymphoid 
and non-lymphoid compartments. 
a 
BOX 1. ANALOGIES BETWEEN IMMUNE RESPONSES 
TO INFECTIONS OR TRANSPLANTS 
b IR» V Of PL c IR «V or PL 
hnmuneignor;mce,;. Sterilizing immune 
OfM()fLp.res~n~.;;. eliminationofMof l 
dIR<VQfPL<i' .......... 8IR~VorPL 
M- or l-dependent partial 
deJetionaltolerance 
and/or memory 
More complete MOIl:.' 
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Persistence of strong immune 
responses; large quantity 
of M or l antigen 
'----,--,..---,-....... . 
The analogies between the adaptive immune response or nO~;~8sponse 
(dashed IInes)indt.iee~tbythe antigen of non-cytopathic microorganisms' 
(M) and the analog.o.\JS migratory leukocytes (L) of allografts ($oHdlines) 
have been obscured'by the presence of contemporaneous host-versus-
graft (HVG) and graft~versus-host (GvH) responses after transplantation 
and the additional factor of therapeutic immunosuppression. Under 
circumstances of both infection and transplantation, the immune response 
or non-response is regulated mainly by the migration and localization of 
the antigen. a. If the antigen fails to reach (}~gf.nized host lymphoid tissue, ~ 
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,as occurs with the extra lymphatic spread of an infection (for example, the 
'~iluman papilloma (wart) virus), there is no immune response (immune 
"ignorance), Similarly, avoidance of host lymphoid organs by transplanting 
~:"tissue to privileged sites or by depleting the allograft of passenger leuko-
',cytes might allow prolonged survival of "Stone-Lafferty" transplants, 
without evolution of donor-specific non-reactivity providing the mobile 
'antigen (L) remains extra lymphatic Rejection of the graft can often be 
precipitated by leakage of graft cells into the blood or lymph circulation 
(for example, after an infection or trauma [S] or an immunizing injection 
,of donor cells [6, 29]. b. Illustrates the immune elimination of a spreading 
non-cytopathic microorganism that has reached host lymphoid organs and 
induced an antigen-specific response. The outcome is comparable with the 
rejection of an outlying organ after its, passenger leukocytes migrate to 
host lymphoid organs and induce an anti-donor response. After complete 
removal of the antigen, the immune response subsides. c. Depicts how the 
persistence of mobile live antigen that has access to host lymphoid organs 
can exhaust and delete the antigen-specific immune response. With infec-
tion, this might result in a stable carrier state (for example, the viral 
hepatitides, or lymphocytic choriomeningitis virus infestation). The trans-
plant analogy is "complete" repopulation of a recipient by donor bone' 
. marrow (BM}-derived cells after pure stem-ceJl transplantation to a severe 
combined immune deficiency (SCI D) mouse, or after the less complete 
replacement (macrochimerism) with clinical 8M transplantation to a host 
whose immune response is weakened in advance by cytoablation or cytoc 
reduction. 'This kind of tolerance in organ recipients is most often 
associated with macrochimerism [39]. d. Represents the acute control ·of 
an infection by incomplete elimination of microorganisms, resultingih 
cellular plus antibody "memory" sustained by the residual live antigen (for 
example, herpesvirus). In the transplantation analogy, partial deleticmal 
tolerance induced at the outset under immunosuppression might be 
sustained by the residual donor cells {microchimerism) with, or sometimes 
without, the aid of immunosuppression. e. Shows more completeelimina-
tion of microorganisms than in (d) with "memory" (for example, 
tuberculosis or measles). In the transplantation analogy, survival of the 
minority population of leukocytes requires continuous immunosuppres-
sion. f. Illustrates the survival of a large quantity of microorganisms 
despite a strong persistent immune response, resulting in acute-chronic 
infection and a spectrum of immunopathology (for example, chronic 
aggressive hepatitis). The transplantation analogy is chronic rejection or 
GvHD, which might be refractory to treatment with immunosuppression. 
With less-complete deletion. cells that survive primary exposure to lymphoid 
organs leave the blood and lymphoid tissues after 30-60 days and move to 
host non-parenchymal tissues and organs (for example, skin and heart [32, 
46]) or back to the transplanted organ [47]. If sufficient numbers of these cells 
steadily emigrate from the extralymphatic sites to host lymphoid organs, the 
clonal exhaustion induced at the outset might be perpetuated with or without 
maintenance immunosuppression (box Id, e), If this traffic is minimal or 
irregular. however. the donor-specific responses might lead instead to acute 
400 Greffe d'organes 
(or chronic) organ rejection or permanent recipient sensitization; experimental 
variables that might tip the balance towards tolerance or rejection have been 
shown by Anderson and Matzinger [48] in mouse experiments. Even with the 
sustained presence of chimerism, the persistence of CTL and antibody 
responses might result in chronic rejection or GvHD (box If). 
What regulates alloimmune responses? 
We have not discussed here the large body of historical [2] and recent work 
indicating the potential importance of immunoregulatory T cells and other 
changes in the host immune response for the mediation of immunity or toler-
ance. Particularly intense interest has focused on antigen-nan-specific [49] 
and antigen-specific T cells [50] that can downregulate both autoimmune and 
alloimmune responses. In addition, immature donor dendritic cells might 
prolong organ allograft survival [51] in contrast to mature dendritic cells that 
efficiently elicit rejection [41]. 
Immunoregulation by such subsets of special recipient or donor immune cells, 
alone or in concert [52], could be important in future strategies of clinical 
transplantation. The same might be true of controlled changes in the host 
cytokine profile, or of the deliberate production of idiotypic or "enhancing" 
antibodies. Elucidation of these frequently reported, but still poorly under-
stood, regulation mechanisms will be necessary for their efficient exploitation. 
For now, we argue that the clinical and experimental observations in trans-
plantation are most comprehensible in terms of antigen dose, localization and 
time during which the antigen is in organized lymphoid organs. 
Clinical implications 
From the historical perspective reviewed here, it is possible to analyse what has 
been, and what might be, accomplished in clinical transplantation. Except for 
Stone-Lafferty grafts, the persistence of donor haematopoietic cells (that is, 
chimerism) above some threshold required to maintain the clonal exhaustion 
induced at the outset is a necessary condition for long allograft survival. Recip-
rocal deletion of the characteristic double immune response of transplantation 
evolves spontaneously in some experimental organ transplant models (espe-
cially with leukocyte-rich liver allografts) [26], but immunosuppression is 
usually required to prevent one immune cell population from destroying the 
other (that is, rejection or GvHD) long enough for the deletion to occur (fig. 2). 
However, the chimerism-dependent clonal exhaustion, might be subverted by 
inappropriate post-transplant immunosuppression. Although over-immunosup-
pression can shut down clonal activation and prevent organ allograft rejection, 
which allows many of the donor leukocytes to survive and migrate to non-
lymphoid sites, the further movement and pleiotropic immunological effects of 
these cells is unpredictable. Consequently, neither the presence nor quantity of 
microchimerism can be used to accurately guide management [31. 32, 39]. 
By contrast, the donor-specific clonal expansion of the conventional BM 
recipient is reduced enough by prior cytoablation to be efficiently deleted by 
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the donor leukocytes before these infused cells are rejected, with minimal 
dependence on immunosuppression, The widespread use of combined BM-
organ transplantation in cytoablated recipients has been barred so far by the 
many parameters involved, of which the most restrictive is the need for a 
histocompatible donor for avoidance of GvHD, 
'::,", . ,.... .. '.' 
't,tExcept for Stone-Lafferty grafts, the persistence of'donor'haematopoietic 
:'-rells{thatis,chimerism).,. is a necessaryconditionforlongaUOgfaftsurvival. n 
',' ,". . 
Compromise strategies between the radically different regimens of BM and 
organ transplantation have been extensively tested. The prototype compromise 
consists of donor BM-cell infusion after weakening the recipient's immune 
responsiveness in advance by non-myelotoxic cytoreduction (for example, with 
sublethal irradiation or anti-lymphoid antibody preparations), and then the use 
of low doses of immunosuppression after transplantation. Production of "mixed 
macrochimerism" with acceptably few GvHD complications has been reported 
in rodents and inbred miniature pig organ-transplant models, and in a small 
series of patients with haematological disorders given BM cells from one HLA 
haplotype-matched familial donors [53]. In simpler non-conditioning protocols 
first used clinically in 1976 by Monaco and co-workers [54], donor BM cells 
have been administered to human organ recipients treated with heavy (that is, 
potentially anti-tolerogenic) conventional immunosuppression. Despite a mani-
fold increase in microchimerism in several trials, drug freedom has not been 
achieved except, apparently, in recent recipients of familial kidneys who were 
given megadoses of donor BM cells in Ahmedabad, India [55]. 
The value of donor pretreatment combined with minimal post-transplant immu-
nosuppression has been suggested by the permanent donor-specific tolerance 
achieved without adjunct BM cells in 12 monkey kidney recipients that were 
conditioned with a depleting dose of immunotoxin and then treated with a 14-
day course of deoxyspergualine afterward [56]. Although such short-term 
protocols regularly allow the induction of tolerance in rodents, they have not 
been used clinically. In the historical clinical experience, tolerance after human 
kidney transplantation has been rarely observed, and almost exclusively when 
the "weak" immunosuppressant azathioprine was administered before and after 
transplantation, adding prednisone only for overt rejection [26]. Drug indepen-
dence has been observed far more frequently after transplantation of the liver, 
but in large numbers only when the original immunosuppression was with 
azathioprine-based regimens that included pretreatment with ALG, or in 
patients who were weaned from tacrolimus [57, 58]. 
It might be possible to achieve drug-free tolerance with organs less well-
endowed with leukocytes than the liver, using a clinical protocol of host condi-
tioning with ALG and minimal post-transplant immunosuppression that was 
introduced in J 966 (ref. 27), but ultimately abandoned. Armed with modern 
drugs, including powerful anti-lymphoid antibody agents, a markedly reduced 
need for early and maintenance immunosuppression (including nearly complete 
elimination of prednisone) has been reported from several centres. In Cambridge 
402 Greffe d'organes 
(United Kingdom), CaIne et al. [59] have treated cadaver kidney recipients with 
a few perioperative doses of a humanized depleting anti-CD52 monoclonal anti-
body (T and B cell plus monocyte reactive), followed by low-maintenance doses 
of cyclosporine alone. 
, '. - , . . 
"The.?r?!Ically,jt~l:1()ukj b~~ossibleJflri,thefutlire to apply immunosuppres-
.. sion.~pWor)~ijW&:i:i~tjIT!~I~!i~f'LinJ~~.~tle ri~~tbalanced way to either 
achieve.lmmun()logi~l;l~iffer;~nc.eQgtlotiil1ce),., or to obtain stable drug-
free and aritfgEm-depehoent T-cell exhauStion and chimerism." 
. , .. , ,'l',.,-, ", :_~_;';\:' -:,'ir.k,,,?:" _. - _._. '.-, ''-. , 
Conclusion 
Although much of the progress in transplantation has depended on the develop-
ment of increasingly potent immunosuppressants, elucidation of the mechanisms 
of allograft acceptance has set the stage for more discriminating use of these 
agents. Theoretically, it should be possible in the future to apply immunosuppres-
sion andlor immunostimulation in just the right balanced way to either achieve 
immunological indifference (ignorance) in some cases, particularly with 
hormone-producing cells and small organs. or to reliably achieve the perfect equi-
librium of mutual immune reactivity and T-cell exhaustion or to obtain stable 
drug-free and antigen-dependent T-cell exhaustion and chimerism. A universally 
applicable protocol for organ transplantation will probably be some modernized 
version of the empirically derived flexible formulas that originally made organ 
transplantation a practical patient service. The key therapeutic principles are: first, 
recipient pretreatment using antibodies or other modalities for conditioning; and 
second, rninimal short-term immunosuppression after transplantation. The value 
of adjunct donor haematolymphopoietic cells should then become apparent. 
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Clonal exhaustion. - A state of non-reactivity when all precursor lymphocytes are 
induced by persistent antigen(s) to become effector cells, purging the immune-
response repertoire of this specificity(s). 
Clonal selection. - In Burnet's original hypothesis (1949), antibody synthesis 
occurred after an antigen locked onto a membrane-bound receptor (a verSiOn 
of the antibody) at the surface of an immunocyte. In the mid-to-Iate 1950s, 
this event was postulated to be clonal by Jerne, Talmage and Burnet. 
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Freemartin cattle. - "Fraternal twins" whose two placentas fuse allowing fetal 
cross circulation, with induction of mutual specific nonreactivity. 
Graft-versus-host disease (GvHD). - The immune reaction against a graft 
recipient mounted by immune-competent cells of a graft. 
Host versus graft (HVG). - The immune reaction mounted by the host against 
grafted tissue or an organ from the same species (alloresponse) or a different 
species (xenoresponse). 
Immune ignorance. - Failure of the immune response to recognize the pres-
ence of antigen that does not reach organized lymphoid tissue. 
Neonatal tolerance. - The development of specific immune non-reactivity to 
antigen introduced during fetal or early postnatal life, before maturation of the 
immune system. 
Non-cytopathic microorganism. - A virus, bacteria, protozoa, fungus or 
microparasite that does not kill host cells and can be accommodated in ways 
that allow the coexistence of host and pathogen. 
Mixed lymphocyte reaction (MLR). - A tissue-culture technique introduced 
by Barbara Bain and by Fritz Bach and Kurt Hirschorn in 1964 for in vitro 
testing of T-cell reactivity. 
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